海南葫芦娃药业集团股份有限公司2025 年半年度报告 公司代码：605199 公司简称：ST 葫芦娃 海南葫芦娃药业集团股份有限公司 海南葫芦娃药业集团股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人刘景萍、主管会计工作负责人于汇及会计机构负责人（会计主管人员）李伟声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 报告期内，公司不进行利润分配或公积金转增股本 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质性承诺，敬请投 资者注意投资风险 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 ...

Core Viewpoint - The report highlights the financial performance and operational strategies of Guangxi Wuzhou Zhongheng Group Co., Ltd. for the first half of 2025, emphasizing growth in net profit and strategic initiatives in the pharmaceutical and health sectors [1][2]. Company Overview and Financial Indicators - The company reported a total revenue of approximately 1.45 billion yuan, representing a 2.84% increase compared to the same period last year [2]. - The total profit decreased by 19.38% to approximately 27.73 million yuan, while the net profit attributable to shareholders increased by 23.59% to approximately 27.08 million yuan [2]. - The net cash flow from operating activities showed a significant decline of 132.23%, amounting to approximately -69.18 million yuan [2]. - As of June 30, 2025, the total assets reached approximately 11.03 billion yuan, a slight increase of 0.49% from the end of the previous year [2]. Business Operations - Zhongheng Group focuses on pharmaceutical manufacturing, with nine key subsidiaries, including Wuzhou Pharmaceutical, which specializes in traditional Chinese medicine [3][4]. - The company aims to enhance the quality of life through its mission of "producing quality Chinese medicine to protect public health" [3][4]. - Wuzhou Pharmaceutical has a rich history and is recognized as a leading enterprise in the production of traditional Chinese medicine, holding numerous production approvals and patents [3][4]. Industry Context - The pharmaceutical manufacturing industry in China faced challenges in the first half of 2025, with a slight decline in revenue and profit among large-scale enterprises [9]. - The aging population in China is expected to drive demand for healthcare products, with projections indicating that the population aged 65 and above will reach 220 million by the end of 2024 [9]. - The industry is undergoing structural changes, with a focus on innovation and international expansion as key growth drivers [10]. Strategic Initiatives - The company is actively pursuing innovation in drug development and has established a comprehensive research and development framework to support new product launches [17]. - Zhongheng Group is enhancing its marketing strategies and expanding its distribution channels to improve market penetration and sales performance [16][17]. - The company has implemented a three-pronged development strategy focusing on sales-driven revenue growth, investment optimization, and strengthening research capabilities [14][15].

上海皓元医药股份有限公司 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》和《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》（以下简称"《自律监管指引 1 号》"）的规 定，将上海皓元医药股份有限公司（以下简称"本公司"或"公司"）2025 年 半年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）2024 年度向不特定对象发行可转换公司债券实际募集资金金额和资 金到账时间 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可[2024]1289号）同意，公司向不 特定对象发行82,235.00万元的可转换公司债券，期限6年，每张面值为人民币100元， 发 行 数 量为822,350 手（ 8,223,500 张）。 本次发 行的募集资 金总额 为人民 币 （特殊普通合伙）于2024年12月5日出具了《验资报告》（容诚验字[2024]200Z0069 号）。 公司对募集资金采用专户存储，设 ...

吉林亚泰（集团）股份有限公司2025 年半年度报告 公司代码：600881 公司简称：亚泰集团 吉林亚泰（集团）股份有限公司 吉林亚泰（集团）股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 一、 未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 董事 韩冬阳 工作原因 秦 音 独立董事 邴 正 工作原因 杜 婕 二、 本半年度报告未经审计。 三、 公司负责人陈铁志、主管会计工作负责人高德才及会计机构负责人（会计主管人员）高德 才声明：保证半年度报告中财务报告的真实、准确、完整。 四、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 五、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的发展战略、未来计划等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 六、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 七、 是否存在违反规定决策程序对外提供担保的情况 否 八、 是 ...

奥锐特药业股份有限公司2025 年半年度报告 公司代码：605116 公司简称：奥锐特 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 奥锐特药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人彭志恩、主管会计工作负责人王袖玉及会计机构负责人（会计主管人员）王袖 玉声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险 ...

| | 上海医药集团股份有限公司2025 | 年半年度报告摘要 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司 A | 股代码：601607 | 公司简称：上海医药 | | | | | | | | | | | | | H 公司 股代码：02607 | | 公司简称：上海醫藥 | | | | | | | | | | | | | | 上海医药集团股份有限公司 | | | | | | | | | | | | | | | 上海医药集团股份有限公司2025 | 年半年度报告摘要 | | | | | | | | | | | | | | 第一节 重要提示 | | | | | | | | | | | | | | 展规划，投资者应当到 | http://www.sse.com.cn | http://www.hkexnews.hk 网站仔细阅读半年度报告 | | | | | | | | | | | | | 全文。 | | | | | | | | | ...

Mergers and Acquisitions - Jia Yuan Technology plans to invest 500 million yuan to acquire a stake in Wuhan Endatong Technology Co., Ltd, with 150 million yuan for share transfer and 350 million yuan for capital increase, resulting in a 13.587% ownership stake [1] - SMIC is planning to issue A-shares to purchase minority stakes in its subsidiary, SMIC North, with stock suspension expected for no more than 10 trading days starting September 1, 2025 [2] - Aier Eye Hospital intends to acquire partial stakes in three medical institutions for 105 million yuan to enhance its "graded chain" development model [3] Performance Disclosure - China Railway reported a 5.93% decline in revenue to 511.09 billion yuan and a 17.17% decrease in net profit to 11.83 billion yuan for the first half of 2025 [4] - China Rare Earth achieved a net profit of 162 million yuan, reversing a loss of 244 million yuan from the previous year, with a 62.38% increase in revenue to 1.875 billion yuan [5] - Yunnan Baiyao's revenue grew by 3.92% to 21.257 billion yuan, with a net profit increase of 13.93% to 3.633 billion yuan [6] - China Shipbuilding reported a 11.96% increase in revenue to 40.325 billion yuan and a 108.59% rise in net profit to 2.946 billion yuan [7] - BeiGene turned a net loss of 2.88 billion yuan from the previous year into a profit of 450 million yuan, with a 46.03% increase in revenue to 17.52 billion yuan [8] Shareholding Changes - Kweichow Moutai's controlling shareholder plans to increase its stake by 3 to 3.3 billion yuan within six months, based on confidence in the company's long-term value [9] - Huasheng Tiancheng's director and supervisor plan to reduce their holdings by a total of up to 1% due to personal financial needs [10] - Zhejiang Wen Film's shareholder plans to reduce holdings by up to 0.43% for personal financial needs [11] - Chenxin Pharmaceutical's major shareholder plans to reduce holdings by up to 1% for funding requirements [12] Investment Activities - Yinglian Co. plans to invest 918 million yuan in a can lid manufacturing project, expected to generate over 2.158 billion yuan in annual revenue [13] - Zhiyang Innovation intends to invest 20 million yuan to establish a wholly-owned subsidiary to promote embodied intelligence technology innovation [14]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][8]. Core Insights - In the first half of 2025, the company achieved a revenue of 625 million yuan, representing a year-on-year growth of 24.40%, and a net profit attributable to shareholders of 119 million yuan, up 21.84% year-on-year [2]. - The sales gross margin was 73.07%, a decrease of 3.79 percentage points compared to the previous year, while the net profit margin was 17.15%, down 1.92 percentage points year-on-year [2]. - The high-temperature alloy segment saw a significant revenue increase of 73.34% year-on-year, reaching 165 million yuan, although its gross margin decreased by 7.18 percentage points to 25.73% [3]. - The company has signed a three-year supply agreement with Siemens, indicating strong customer expansion in the high-temperature alloy business [5][7]. Financial Performance - For Q2 2025, the company reported a revenue of 290 million yuan, a year-on-year increase of 36.81%, but a quarter-on-quarter decrease of 13.33% [4]. - The net profit for Q2 2025 was 47 million yuan, reflecting a year-on-year growth of 44.94% but a quarter-on-quarter decline of 35.73% [4]. - The company expects revenues of 1.419 billion yuan, 1.809 billion yuan, and 2.258 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 261 million yuan, 342 million yuan, and 435 million yuan [8][10]. Business Segments - The medical products segment, particularly the Jinshuangqi and Dingjunsheng products, has seen revenue growth of 12.52% and 17.47% respectively in the first half of 2025 [3][12]. - The company is advancing its dual-base construction in the pharmaceutical sector, with significant progress in its biopharmaceutical R&D headquarters and industrialization base [7].

（记者 王晓波） 每经AI快讯，三生国健（SH 688336，收盘价：52.6元）8月29日晚间发布公告称，公司第五届第十一次 董事会会议于2025年8月29日以现场和通讯结合表决的方式召开。会议审议了《关于公司<2025年度"提 质增效重回报"行动方案半年度评估报告>的议案》等文件。 每经头条（nbdtoutiao）——近120个品牌、1600辆车逐鹿西南！下半年国内首个A级车展开幕：新能 源"第三极"将改写车市格局 2024年1至12月份，三生国健的营业收入构成为：医药制造占比83.02%，CDMO业务占比10.19%，授权 许可占比5.54%，其他业务占比1.25%。 截至发稿，三生国健市值为324亿元。 ...

8月29日晚，万邦德（002082）公告称，全资子公司万邦德制药集团有限公司的2.2类新药石杉碱甲控释 片用于治疗轻、中度阿尔茨海默病型痴呆的II/III期关键注册临床试验，于近日完成首例受试者入组。 公告显示，石杉碱甲是用于改善认知功能的胆碱酯酶抑制剂，临床前研究展现出延缓阿尔茨海默病疾病 进展的潜力及广泛的综合获益，包括对β淀粉样蛋白的降低作用，抗炎、抗氧化应激以及神经元保护作 用，有望成为具有广谱抗阿尔茨海默病型痴呆的药物。 石杉碱甲控释片是万邦德自主研发的用于治疗轻、中度阿尔茨海默病型痴呆的2.2类新药，采用双相控 释技术，平缓药物释放峰谷曲线，并延长药物体内释放时间，从而实现快速起效，减少不良反应，提升 给药剂量与良好的安全性。同时，控释技术支持每天一次给药，提高患者的用药便利性和长期依从性。 值得注意的是，本次开展的II/III期临床研究，是中国目前已知规模最大的阿尔茨海默病注册研究。研究 采用多中心、随机、双盲双模拟的设计，同时设有安慰剂和阳性药双对照，更加全面地评价疗效与安全 性。 据悉，万邦德深耕医疗大健康产业，已形成医药制造与医疗器械板块双头并进的格局。2025年上半年， 公司实现营业收入 ...